Treatment of seborrheic dermatitis: The efficiency of sertaconazole 2% cream vs. tacrolimus 0.03% cream

• Autorzy: Goldust M. , Rezaee E. , Raghifar R. , Hemayat S.
• Języki publikacji: EN

Abstrakty

EN

The treatment of seborrheic dermatitis (SD) includes topical antifungal agents to eradicate Malassezia spp. corticosteroids to treat the inflammatory component of the disease, and keratolytics to remove scale and crust. The aim of this study was to compare the efficiency of sertaconazole 2% cream and tacrolimus 0.03% cream in the treatment of seborrheic dermatitis. In this clinical trial study, sixty patients suffering from SD were studied. Thirty patients received local sertaconazole 2% cream with a recommendation to use the cream twice a day for 4 weeks. In the control group, thirty patients received tacrolimus 0.03% cream twice a day for four weeks. At the time of referral, and 2 and 4 weeks after first visit, the patients were examined by a dermatologist to check the improvement of clinical symptoms. The mean ages of the sertaconazole and tacrolimus groups were 30.98 ± 12.24 and 34.67 ± 10.82, respectively. The highest level of satisfaction (90%) was observed 28 days after sertaconazole use. Only 83.3% satisfaction was noted in the tacrolimus group. The relationship between patient satisfaction and sertaconazole 2% cream receive in 28th day was significant (P=0.006). Sertaconazole 2% cream may be an excellent alternative therapeutic modality for treating seborrheic dermatitis.

Słowa kluczowe

EN

treatment; seborrheic dermatitis; efficiency; sertaconazole cream; tacrolimus cream; drug effect; antifungal agent; Malassezia; human disease

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2013
• Tom: 59
• Numer: 2
• Opis fizyczny: p.73-77,ref.

Twórcy

autor

Goldust M.

• Student Research Committee, Tabriz University of Medical Sciences, Iran

autor

Rezaee E.

• Department of Medicinal Chemistry, Shahid Beheshti University of Medical Sciences, Teheran, Iran

autor

Raghifar R.

• Student Research Committee, Tabriz University of Medical Sciences, Iran

autor

Hemayat S.

• Teheran Azad University of Medical Sciences, Teheran, Iran

Bibliografia

• [1] Item 232: facial dermatitis: seborrheic dermatitis. Annales de Dermatologie et de Vénéréologie 135 (11 Suppl): F197-F199.
• [2] Azimi H., Majidi J., Estakhri R., Goldust M. 2013. IgG antibodies in patients with pemphigus vulgaris before and after diagnosing with immunofluore - scence. Pakistan Journal of Biological Sciences 16: 589-592.
• [3] Nejad S.B., Qadim H.H., Nazeman L., Fadaii R., Goldust M. 2013. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pakistan Journal of Biological Sciences 16: 570-574.
• [4] Sampaio A.L., Mameri A.C., Vargas T.J., Ramos-e-Silva M., Nunes A.P., Carneiro S.C. 2011. Seborrheic dermatitis. Anais Brasileiros de Dermatologia 86:1061-1071.
• [5] Golforoushan F., Azimi H., Goldust M. 2013. Efficacy of vitamin E to prevent dermal complications of Isotretinoin. Pakistan Journal of Biological Sciences 16: 548-550.
• [6] Razi A., Golforoushan F., Bahrami A., Nejad S.B., Goldust M. 2013. Evaluating of dermal symptoms in hypothyroidism and hyperthyroidism. Pakistan Journal of Biological Sciences 16: 541-544.
• [7] Treadwell P.A. 2011. Papulosquamous disorders: atopic dermatitis, psoriasis, seborrheic dermatitis, and nickel contact dermatitis. Adolescent Medicine: state of the art reviews 22: 157-168.
• [8] Qadim H.H., Golforoushan F., Nejad S.B., Goldust M. 2013. Studying the calcium serum level in patients suffering from psoriasis. Pakistan Journal of Biological Sciences 16: 291-294.
• [9] Goldust M., Golforoushan F., Rezaee E. 2011. Treatment of solar lentigines with trichloroacetic acid 40% vs. cryotherapy. European Journal of Dermatology 21: 426-427.
• [10] Waldroup W., Scheinfeld N. 2008. Medicated shampoos for the treatment of seborrheic dermatitis. Journal of Drugs in Dermatology 7: 699-703.
• [11] Golfurushan F., Sadeghi M., Goldust M., Yosefi N. 2011. Leprosy in Iran: an analysis of 195 cases from 1994-2009. Journal of Pakistan Medical Association 61: 558-561.
• [12] Mohebbipour A., Saleh P., Goldust M., Amirnia M., Zadeh Y.J., Mohamadi R.M. et al. 2012. Treatment of scabies: comparison of ivermectin vs. lindane lotion 1%. Acta Dermatovenerologica Croatica 20: 251-255.
• [13] Schmidt J.A. 2011. Seborrheic dermatitis: a clinical practice snapshot. Nurse Practice 36: 32-37.
• [14] Goldust M., Rezaee E., Raghifar R. 2013. Comparison of oral ivermectin versus crotamiton 10% cream in the treatment of scabies. Journal of Toxicology – Cutaneous and Ocular Toxicology (in press).
• [15] Lotti T., Goldust M., Rezaee E. 2013. Treatment of seborrheic dermatitis, comparison of sertaconazole 2% cream vs. ketaconazole 2% cream. Journal of Dermatological Treatment (in press).
• [16] Lee Y.W., Byun H.J., Kim B.J., Kim D.H., Lim Y.Y., Lee J.W. et al. 2011. Distribution of Malassezia species on the scalp in korean seborrheic dermatitis patients. Annales de Dermatologie et de Vénéréologie 23:156-161.
• [17] Goldust M., Rezaee E. 2013. The efficacy of topical ivermectin vs. malation 0.5% lotion for the treatment of scabies. Journal of Dermatological Treatment (in press).
• [18] Del Rosso J.Q. 2011. Adult seborrheic dermatitis: a status report on practical topical management. Journal of Clinical and Aesthetic Dermatology 4: 32-38.
• [19] Rovelli F., Mercuri S.R., Naldi L. 2011. Seborrheic dermatitis in clinical practice. Recenti Progressi in Medicina 102: 26-133.
• [20] Menzinger S., Laffitte E. 2011. Seborrheic dermatitis: clinical manifestations and management. Revue Médicale Suisse 7: 752-758.
• [21] Palamaras I., Kyriakis K.P., Stavrianeas N.G. 2012. Seborrheic dermatitis: lifetime detection rates. Journal of the European Academy of Dermatology and Venereology 26: 524-526.
• [22] Kim B.S., Kim S.H., Kim M.B., Oh C.K., Jang H.S., Kwon K.S. 2007. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an openlabel clinical study in Korean patients. Journal of Korean Medical Science 22: 868-872.
• [23] Arora V., Arora S. 2007. Management of infantile seborrheic dermatitis. American Family Physician 75: 807.
• [24] Rallis E., Korfitis C., Gregoriou S., Rigopoulos D. 2007. Assigning new roles to topical tacrolimus. Expert Opinion on Investigational Drugs 16: 1267-1276.
• [25] Ling M.R. 2001. Topical tacrolimus and pimecrolimus: future directions. Seminars in Cutaneous Medicine and Surgery 20: 268-274.
• [26] Weinberg J.M., Koestenblatt E.K. 2011. Treatment of interdigital tinea pedis: once-daily therapy with sertaconazole nitrate. Journal of Drugs in Dermatology 10: 1135-1140.
• [27] Croxtall J.D., Plosker G.L. 2009. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs 69: 339-359.
• [28] Papp K.A., Papp A., Dahmer B., Clark C.S. 2012. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults.Journal of the American Academy of Dermatology 67: 11-15.
• [29] Braza T.J., DiCarlo J.B., Soon S.L., McCall C.O. 2003. Tacrolimus 0.1% ointment for seborrheic dermatitis: an open-label pilot study. British Journal of Dermatology 148: 1242-1244.
• [30] Elewski B.E., Cantrell W.C. 2011. An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis. Journal of Drugs in Dermatology 10: 895-899.
• [31] Meshkinpour A., Sun J., Weinstein G. 2003. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. Journal of the American Academy of Dermatology 49: 145-147.
• [32] Elewski B.E. 2009. Safe and effective treatment of seborrheic dermatitis. Cutis 83: 333-338.